Market Place
Sourcing Support
AVM Biotechnology Selected by the National Cancer Institute to Present
11 Sep 2023 //
BUSINESSWIRE
AVM Bio Announces Solid Tumor & Blood Cancer Patients Treated with AVM0703
01 Aug 2023 //
BUSINESSWIRE
AVM Biotech Awarded $2M NCI SBIR PII Grant from NIH to Advance AVM0703
14 Jun 2022 //
BUSINESSWIRE
AVM Biotechnology to Present Poster Highlighting the Effects of AVM0703
01 Jun 2022 //
BUSINESSWIRE
AVM Bio Founder and CSO to Present Company Information and Trial Progress
19 Apr 2022 //
BUSINESSWIRE
AVM Biotechnology Awarded $1.6M Phase II SBIR Grant to Study AVM0703’s Potential
05 Apr 2022 //
BUSINESSWIRE
AVM Biotech Expands C-Suite in Anticipation of 2023 Commercialization Efforts
09 Mar 2022 //
BUSINESSWIRE
FDA Approves Accelerated Dosing in Non-Hodgkin`s Lymphoma/Leukemia
13 Jul 2021 //
PRNEWSWIRE
AVM Announces Full Enrollment of First Cohort of Relapsed/Refractory
07 Apr 2021 //
PRNEWSWIRE
Seattle AVM Biotechnology announces second IND for AVM0703
16 Sep 2020 //
BIOSPACE
AVM Biotechnology Expands Executive Team in Preparation Onco & COVID-19 Trials
08 Jul 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.